Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Genetic markers

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    519 result(s) found for: Genetic markers. Displaying page 1 of 26.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-001174-33 Sponsor Protocol Number: 28612 Start Date*: 2008-12-30
    Sponsor Name:Merck Serono International S.A., A branch of Laboratoires Serono S.A.
    Full Title: A mulitnational, multicenter, exploratory pharmacogenomics trial to test the importance of identified genetic markers, and potentially identify new markers of various ovarian responses to GONAL-f® ...
    Medical condition: Females undergoing assisted reproductive technology (ART), in vitro fertilisation (IVF) or intra cytoplasmic sperm injection (ICSI)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021930 Infertility NOS LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-013272-47 Sponsor Protocol Number: iSPOT-A Start Date*: 2009-08-19
    Sponsor Name:BRC operations Pty. Ltd
    Full Title: International Study to Predict Optimized Treatment - in Attention-Deficit and Hyperactivity Disorder
    Medical condition: Attention Deficit Hyperactivity Disorder
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018559-84 Sponsor Protocol Number: AMB-WEI-1052-I Start Date*: 2010-07-20
    Sponsor Name:Medizinische Fakultät der technischen Universität Muenchen
    Full Title: AMBITIOUS Atopic Dermatitis Biomarker Identification Trial in Omalizumab Usage Single- arm trial to identify potential markers underlying variability in response to Omalizumab (Xolair®) treatment i...
    Medical condition: AMBITIOUS is a trial to identify potential markers underlying variability in response to Omalizumab (Xolair®) treatment in atopic dermatitis Atopische Dermatitis is a common inflammatory skin disea...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10029264 Neurodermatitis aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000460-10 Sponsor Protocol Number: EMR200104_10 Start Date*: 2011-08-03
    Sponsor Name:Merck Serono SA
    Full Title: First year growth response associated genetic markers validation Phase IV open-label study in Growth Hormone Deficient and Turner Syndrome pre-pubertal children : the PREDICT Pharmacogenetics V...
    Medical condition: idiopathic growth hormone deficienty Turner Syndrome
    Disease: Version SOC Term Classification Code Term Level
    13.1 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    13.1 10010331 - Congenital, familial and genetic disorders 10045181 Turner's syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003596-17 Sponsor Protocol Number: CMAS825D12201 Start Date*: 2021-03-09
    Sponsor Name:Novartis Pharma AG
    Full Title: A three-period multicenter study, with a randomized withdrawal, double-blinded, placebo-controlled design in Period 2 to evaluate the clinical efficacy, safety and tolerability of MAS825 in NLRC4-G...
    Medical condition: NLRC4-GOF, AIFEC (autoinflammation with infantile enterocolitis)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10010331 - Congenital, familial and genetic disorders 10084306 Autoinflammation with infantile enterocolitis PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005255-17 Sponsor Protocol Number: Start Date*: 2014-09-05
    Sponsor Name:University of Leeds
    Full Title: Chronotherapeutic lifestyle intervention for diabetes and obesity to reset the circadian rhythm and improve cardiometabolic risk in the European population
    Medical condition: first-degree relatives of individuals with type 2 diabetes.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004122-17 Sponsor Protocol Number: iSPOT-D Start Date*: 2008-08-29
    Sponsor Name:BRC operations Pty. Ltd.
    Full Title: International Study to Predict Optimised Treatment - in Depression iSPOT-D
    Medical condition: Patients suffering from major depressive disorder (MDD) as well as healthy control participants. Only patients will receive medication which will be 'treatment as usual'.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-003617-16 Sponsor Protocol Number: D6997C00003 (9238IL/0065) Start Date*: 2004-12-24
    Sponsor Name:AstraZeneca Österreich GmbH
    Full Title: A Randomized, Open-label, Multicenter, Phase II Study Comparing the Effects on Proliferation and the Efficacy and Tolerability of Fulvestrant (FASLODEX™) 500 mg with Fulvestrant (FASLODEX™) 250 mg ...
    Medical condition: Postmenopausal Women with Estrogen Receptor Positive Breast Cancer (T2, 3, 4b, N0-3, M0)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002319-86 Sponsor Protocol Number: DIAN-Obs-BCN Start Date*: 2019-03-20
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: Dominantly Inherited Alzheimer Network - DIAN
    Medical condition: Alzheimer disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002124-17 Sponsor Protocol Number: IMO-AFLI-2013-01 Start Date*: 2013-10-04
    Sponsor Name:Fundació de Recerca de L?Institut de Microcirurgia Ocular
    Full Title: Phase IV study to evaluate genetic variants of VEGF pathway as biomarkers of VEGF Trap-Eye treatment efficacy in subjects with neovascular age-related macular degeneration (wAMD).
    Medical condition: Wet age-related macular degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-000524-26 Sponsor Protocol Number: UMCU2014-VASC-CO-001 Start Date*: 2015-05-19
    Sponsor Name:University Medical Center Utrecht
    Full Title: A randomized, placebo-controlled, double blind, cross-over trial to study the effects of adding bezafibrate to standard lipid lowering therapy on postprandial lipids in patients with familial dysbe...
    Medical condition: Familial Dysbetalipoproteinemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001923-30 Sponsor Protocol Number: TN-20 Start Date*: 2016-09-26
    Sponsor Name:TRIALNET COORDINATING CENTER AT THE UNIVERSITY OF SOUTH FLORIDA
    Full Title: Exploring Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus
    Medical condition: Type 1 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10066284 Diabetes prophylaxis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004158-33 Sponsor Protocol Number: CYP3A4/5+PGPinRenalTx Start Date*: 2008-09-17
    Sponsor Name:Department of Nephrology and Renal Transplantation, KU Leuven
    Full Title: CYP3A4/5 and PGP activity in renal transplantation. A study assessing in vivo hepatic and intestinal CYP3A4/5 and PGP activity in kidney transplant recipients and its relationship with genetic and...
    Medical condition: Effect of genetic (single nucleotide polymorphisms of genes encoding drug metabolising enzymes and drug transporters) and non-genetic factors (e.g. age, time after transplantation, concommitant med...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038533 Renal transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020912-12 Sponsor Protocol Number: VP-VEC-162-3202 Start Date*: 2010-08-26
    Sponsor Name:Vanda Pharmaceuticals Inc.
    Full Title: Open-label safety study of a 1-year 20 mg dose regimen of tasimelteon for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD) in blind individuals with no light perception.
    Medical condition: Non-24 Hour Sleep-Wake Disorder
    Disease: Version SOC Term Classification Code Term Level
    12.1 10013419 Disruptions of 24 hour sleep-wake cycle LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002795-13 Sponsor Protocol Number: TACRO-Omics Start Date*: 2020-04-23
    Sponsor Name:Fundación de Investigación Hospital Universitario La Paz
    Full Title: Identification of "omic" biomarkers and their inter and intra-individual variability that allow improvement in the individualization of tacrolimus: uncontrolled clinical trial in pediatric patients...
    Medical condition: Pediatric patients with renal transplantation (under stable treatment with tacrolimus as immunosuppressant)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011115-20 Sponsor Protocol Number: NordLOTS protocol step 3 1.1 Start Date*: 2009-08-14
    Sponsor Name:The Centre for Child and Adolescent Mental Health, Eastern and Southern Norway (R.BUP)
    Full Title: Nordic Longterm OCD treatment Study: A Nordic Multicenter treatment study evaluating a stepped care model based on the "Expert Clinical Guidelines". The study is performed with no sponsor from phar...
    Medical condition: Obsessive Compulsive Disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049596 Obsession LLT
    9.1 10010219 Compulsions LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Ongoing) NO (Ongoing) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-023446-70 Sponsor Protocol Number: Start Date*: 2011-07-22
    Sponsor Name:Med. Univ. Wien, Univ. Klinik für Psychiatrie und Psychotherapie
    Full Title: Neural, Genetic, and Peripheral Correlates of SSRI Pharmaco-Response
    Medical condition: Major Depressive Disorder (MDD) remains to be under-recognized and under-treated, though it is amongst the leading causes of disease burden worldwide. Despite the proven efficacy of modern antidepr...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001501-41 Sponsor Protocol Number: 156-13-208 Start Date*: 2016-01-16
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Multinational Trial to Collect Blood Samples to Explore Potential Genetic/Biomarkers Related to Increased Risk of Liver Injury in Adult Subjects from Prior Tolvaptan Clinical Trials for Autosomal...
    Medical condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD), Patients with Increased Risk of Liver Injury
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-015502-19 Sponsor Protocol Number: EMR200136_022 Start Date*: 2009-12-14
    Sponsor Name:Merck Serono SA – Geneva
    Full Title: A multinational, multicenter, single visit, exploratory pharmacogenetic trial and long-term follow-up of the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Mu...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) DE (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004874-42 Sponsor Protocol Number: TRAFO001 Start Date*: 2009-02-06
    Sponsor Name:Institut für Frauengesundheit GmbH
    Full Title: Evaluation of predictive Factors for the Effectivity of Aromatase Inhibitor Therapy - Offene, prospektive, multizentrische Phase IV-Studie zur Untersuchung des Einflusses von pharmakogenetischen M...
    Medical condition: The study examines the influence of pharmacogenetic markers on the efficacy and side effects in postmenopausal, steroid hormone positive breast cancer patients, who are treated with Letrozol. The p...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 16:14:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA